South San Francisco, CA

Second Genome To Present Biomarker Data in Oncology at Keystone Symposium

January 19, 2021,

READ MORE

Second Genome To Present at Biotech Showcase Digital 2021 Conference

January 11, 2021,

READ MORE

Second Genome Expands Development of CNS Platform to Validate Microbial Products as Therapeutics for Autism Spectrum Disorder

March 26, 2019,

READ MORE

Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For The Treatment Of Nonalcoholic Steatohepatitis (NASH)

January 23, 2019,

READ MORE

Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer

September 26, 2018,

READ MORE

Second Genome Certified as Great Place to Work®

July 30, 2018,

READ MORE

Second Genome Appoints Anupama S. Hoey as Chief Business Officer

July 23, 2018,

READ MORE

Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

April 9, 2018,

READ MORE

Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer

March 5, 2018,

READ MORE

Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study

December 19, 2017,

READ MORE